CCG
BRNS

Catalina Capital Group’s Barinthus Biotherapeutics BRNS Stock Holding History

Catalina Capital Group’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,216
Closed -$12.3K – 212
2024
Q4 		$12.3K Sell
10,216
-10,296
-50% -$12K ﹤0.01% 367
2024
Q3 		$24.4K Buy
20,512
+2,693
+15% +$3.61K 0.01% 341
2024
Q2 		$24.9K Buy
+17,819
New +$40.2K 0.01% 310

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Catalina Capital Group's BRNS Position: Q1 2025 in Review

Catalina Capital Group sold out of Barinthus Biotherapeutics (BRNS) in Q1 2025, closing a stake of 10,216 shares — an estimated $12.3K sold.

Catalina Capital Group first reported a position in BRNS in Q2 2024 and held it in 3 quarters. The position peaked at $24.9K in Q2 2024. 15 funds tracked by Wall St. Rank hold BRNS as of Q1 2025.

  • Catalina Capital Group reported no remaining Barinthus Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Catalina Capital Group sold 10,216 Barinthus Biotherapeutics shares in Q1 2025, an estimated $12.3K.
  • Catalina Capital Group first reported a position in Barinthus Biotherapeutics in Q2 2024 and held it in 3 quarters.
  • Catalina Capital Group's Barinthus Biotherapeutics position peaked at $24.9K in Q2 2024.
  • 15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q1 2025.

Based on Catalina Capital Group's 13F filing for Q1 2025, filed 21 Apr 2025.